Back to search

253 result(s):

prot

INITIAL PLASMA HIV-1 RNA AND CD4+ T-CELL COUNT ARE DETERMINANTS OF VIROLOGICAL OUTCOMES WITH INITIAL INTEGRASE INHIBITOR-BASED REGIMENS: A PROSPECTIVE MULTINATIONAL RESPOND COHORT CONSORTIUM

SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EXPERIENCE WITH THE 2-DRUG REGIMEN DOLUTEGRAVIR AND LAMIVUDINE IN PEOPLE WITH HIV WHO WOULD NOT HAVE MET INCLUSION CRITERIA FOR THE PHASE 3 CLINICAL PROGRAM (ENCORE)

2 YEAR OUTCOMES OF DOLUTEGRAVIR (DTG) + LAMIVUDINE (3TC) IN ART-NAÏVE AND PRE-TREATED PEOPLE LIVING WITH HIV IN GERMANY: REAL-WORLD DATA FROM THE GERMAN URBAN COHORT

HIGH EFFICACY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) IN TREATMENT-NAIVE ADULTS WITH HIV-1 AND HIGH BASELINE VIRAL LOAD (VL): 48-WEEK SUBGROUP ANALYSES OF THE GEMINI-1/-2 AND STAT TRIALS

Can’t find what you’re looking for or would like to discuss our data in person? Contact your MSL

Contact us

NP-GBL-HVX-WCNT-220014 September 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.